source
- Definium's LSD pill shows significant anxiety reduction in Phase 3 trialDefinium Therapeutics announced results of a Phase 3 trial testing its LSD‑based pill DT120 in patients with generalized anxiety disorder. The study enrolled 214 participants who received a single…
- Sentynl inks up to $475M licensing deal to commercialize Mereo’s alvelestat for rare lung diseaseSentynl Therapeutics, a subsidiary of Zydus Lifesciences, signed an agreement to obtain exclusive U.S. rights to market alvelestat, Mereo BioPharma’s investigational therapy for alpha-1 antitrypsin…